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ABSTRACT
OBJECTIVE
To assess the use of proton pump inhibitors (PPIs) to 
treat persistent throat symptoms.
DESIGN
Pragmatic, double blind, placebo controlled, 
randomised trial.
SETTING
Eight ear, nose, and throat outpatient clinics, United 
Kingdom.
PARTICIPANTS
346 patients aged 18 years or older with persistent 
throat symptoms who were randomised according to 
recruiting centre and baseline severity of symptoms 
(mild or severe): 172 to lansoprazole and 174 to 
placebo.
INTERVENTION
Random blinded allocation (1:1) to either 30 mg 
lansoprazole twice daily or matched placebo twice 
daily for 16 weeks.
MAIN OUTCOME MEASURES
Primary outcome was symptomatic response at 16 
weeks measured using the total reflux symptom index 
(RSI) score. Secondary outcomes included symptom 
response at 12 months, quality of life, and throat 
appearances.
RESULTS
Of 1427 patients initially screened for eligibility, 346 
were recruited. The mean age of the study sample 
was 52.2 (SD 13.7) years, 196 (57%) were women, 
and 162 (47%) had severe symptoms at presentation; 
these characteristics were balanced across treatment 
arms. The primary analysis was performed on 220 
patients who completed the primary outcome 
measure within a window of 14-20 weeks. Mean 
RSI scores were similar between treatment arms at 
baseline: lansoprazole 22.0 (95% confidence interval 
20.4 to 23.6) and placebo 21.7 (20.5 to 23.0). 
Improvements (reduction in RSI score) were observed 
in both groups—score at 16 weeks: lansoprazole 17.4 
(15.5 to19.4) and placebo 15.6 (13.8 to 17.3). No 
statistically significant difference was found between 
the treatment arms: estimated difference 1.9 points 
(95% confidence interval −0.3 to 4.2 points; P=0.096) 
adjusted for site and baseline symptom severity. 
Lansoprazole showed no benefits over placebo for 
any secondary outcome measure, including RSI scores 
at 12 months: lansoprazole 16.0 (13.6 to 18.4) and 
placebo 13.6 (11.7 to 15.5): estimated difference 2.4 
points (−0.6 to 5.4 points).
CONCLUSIONS
No evidence was found of benefit from PPI treatment 
in patients with persistent throat symptoms. RSI 
scores were similar between the lansoprazole and 
placebo groups after 16 weeks of treatment and at the 
12 month follow-up.
TRIAL REGISTRATION
ISRCTN Registry ISRCTN38578686 and EudraCT 2013-
004249-17.
Introduction
Persistent throat symptoms are a common presentation 
in primary and secondary care and principally 
comprise hoarseness; the sensation of a lump in the 
throat (globus); repeated throat clearing; mucus in the 
throat, or “catarrh”; cough; and throat discomfort. The 
prevalence of globus alone in middle aged women is 
about 6%,1 with a lifetime ever population incidence 
of more than 40%.2 A quarter of patients attending 
primary care for other conditions might report major 
throat symptoms when questioned.3
Gastroesophageal reflux disease (GORD) affects up 
to 20% of the Western population.4 An association 
between GORD and throat and voice symptoms 
is widely cited—a decade ago more than half of 
British otolaryngologists prescribed proton pump 
inhibitors (PPIs) for throat symptoms.5 GORD and 
related symptoms have been described using a 
variety of terms, including extraoesophageal reflux, 
laryngopharyngeal reflux, and reflux laryngitis. The 
concept of a link between GORD and throat and voice 
symptoms has since become even more popular, with 
open access primary care guidelines advocating PPI 
treatment.6 The few randomised controlled trials that 
have compared PPIs with placebo are heterogeneous 
and generally underpowered.7 By far the largest 
controlled trial included 145 patients8 and found no 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Throat symptoms are a common reason for referral from primary to secondary 
care—the sensation of a lump in the throat affects up to half of the general 
population at some stage
Proton pump inhibitors (PPIs) are widely used in both primary and secondary 
care in the UK as empirical treatment for throat symptoms
Published meta-analyses of PPIs for the treatment of throat symptoms include 
small scale studies of limited value
WHAT THIS STUDY ADDS
This trial found no evidence of benefit for patients with persistent throat 
symptoms who were treated empirically with a PPI
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benefit from treating suspected reflux laryngitis with 
PPIs twice daily compared with placebo twice daily. 
Despite variable quality, recent meta-analyses of small 
randomised controlled trials indicate either no benefit9 
or mild superiority10 11 of PPIs over placebo. Increasing 
use of PPIs, at cost to the National Health Service, has 
become the default treatment for persistent throat 
symptoms in primary and secondary care without 
robust evidence. Inappropriate use of PPIs is a major 
healthcare concern and contributes to polypharmacy, 
risk of drug interactions, and risk of side effects. A US 
study found that the cost of treating extraoesophageal 
reflux symptoms in 281 patients was more than 
fivefold that of the estimated cost of treating patients 
with traditional GORD symptoms,12 with more than 
50% of these costs attributed to prescriptions for PPIs.
We investigated the role of PPIs as pragmatic 
preferred treatment for throat symptoms in primary 
and secondary care.
Methods
This trial was an investigator initiated, multicentre, 
randomised, double blind, placebo controlled 
trial conducted in eight hospitals in the UK. The 
trial protocol was approved by the regional ethics 
committee and has been published previously.13 Both 
an independent data monitoring committee and a trial 
steering committee oversaw the trial.
Patients and presenting characteristics
Participants were adults (≥18 years) newly referred 
to eight secondary care otolaryngology clinics with 
persistent (>6 weeks) unexplained throat symptoms—
principally hoarseness, throat pain, globus sensation, 
throat clearing, postnasal secretions or excess mucus, 
cough, or choking sensation. Given the prevalence of 
minor throat symptoms in the general population, 
we considered patients to be eligible for the trial 
based on symptom severity. At baseline we assessed 
severity using the reflux symptom index (RSI), a well 
established patient self-report questionnaire (see 
supplementary table 1),14 which is widely used in 
voice and general otolaryngology clinics. It is also one 
of the few tools with published data on sensitivity to 
change15 and with normative ranges for the general 
population.16 The last of the nine items of the RSI is 
a composite GORD question covering heartburn, chest 
pain, indigestion, or stomach acid reflux. Although the 
upper limit of the RSI population norm is generally 
taken to be 12 points, at least 5 of the 12 points can 
be achieved by maximum endorsement of dyspepsia 
(item 9). To ensure that patients had a qualifying level 
of severity for the non-dyspepsia items (ie, the throat 
symptoms in question), all participants were required 
to score at least 10 points on items 1 to 8 of the RSI (here 
referred to as RSI-HB to denote the laryngopharyngeal 
RSI items without the heartburn score). We excluded 
patients if laryngopharyngeal endoscopy showed 
disease requiring specific treatment, such as vocal cord 
polyps or malignancy, or they had a contraindication 
to PPIs. Patients currently taking a PPI required a 
wash-out period of four weeks to enter the trial, and 
those taking alginates were required to discontinue 
these drugs. The complete list of inclusion and 
exclusion criteria are published elsewhere.13 To ensure 
consistency across the sites, all participants had access 
to the trial website and introductory video before 
providing written informed consent.
Trial procedures
The active intervention was 30 mg lansoprazole 
twice daily for 16 weeks. The control group received 
matched placebo capsules twice daily for 16 weeks. 
Lansoprazole was chosen as a representative PPI 
because of its popularity and continued inclusion in 
UK national guidance for the treatment of GORD, in 
which the dosage regimen equates to a high or double 
dose.17 No evidence supports the superiority of one 
PPI over another for persistent throat symptoms. The 
participants and research team staff were blinded 
to treatment allocation, which was maintained 
throughout the trial. Participants were assessed at 
baseline (after informed consent) and at 16 weeks 
and 12 months. After the assessment at 16 weeks, 
they were not prescribed any trial drug for symptoms. 
Randomisation was administered centrally through 
the Newcastle Clinical Trials Unit using a secure 
web based system. Patients were randomised using 
permuted random blocks, and allocated 1:1 stratified 
by centre and baseline symptom severity on the basis 
of a dichotomised RSI-HB score (mild ≤20, severe >20) 
to ensure the population reflected persistent throat 
symptoms and not classic GORD symptoms. We used 
severity stratums derived from data in published RSI 
datasets.15 18
Outcome measures
The primary outcome measure was the total RSI score 
(a summation of all nine items) at 16 weeks after 
randomisation. The RSI was scored on a 6 point Likert 
scale (0-5), giving a total range of 0-45 scores (see 
supplementary table 1). A higher score indicates more 
severe symptoms.
The secondary outcomes were compliance with 
the intervention, as measured by reported drugs 
taken and return of unused tablets (treatment kits 
contained a 16 week course of 224 capsules), RSI 
score at 12 months after randomisation, two further 
patient self-report symptom measures—the 34 item 
comprehensive reflux symptom score (CReSS)19 and 
the 43 item laryngopharyngeal health related quality 
of life tool20 (higher scores for both equate to more 
severe symptoms), and utility of baseline laryngeal 
mucosal changes (all participants were assessed by a 
single clinician, who was blind to the symptom scores) 
recorded by the reflux finding score21 as a predictor of 
outcome.
These secondary outcomes were prespecified in 
the published protocol13 and defined in the ISRCTN 
registry. The main trial outcomes (primary outcome 
measure, secondary outcome of RSI score at 12 
months, and adverse events) are reported in EudraCT. 
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Several secondary outcomes were not defined in the 
trial registry owing to an error by the authors and 
therefore must be considered as post hoc additions. 
These were total laryngopharyngeal item RSI score 
(omitting the GORD item, RSI-HB, score 0-40), patient 
post-treatment prediction of allocated intervention, 
and patient satisfaction with the trial. Other than the 
participant post-treatment prediction of allocated 
intervention secondary outcome, the other outcomes 
were defined in the published protocol.
Statistical analysis
For the main analysis of the primary outcome 
measure we used a multivariable multilevel mixed 
effect linear regression to compare the RSI at 16 
weeks after adjustment for the stratification factors 
at randomisation, with centre as a random effect and 
mild or severe baseline severity categories as a fixed 
effect. As the trial proceeded it became clear to the 
trial steering committee that some participants had 
considerably delayed their primary outcome and data 
collection follow-up appointments. The trial steering 
committee recommended that the primary analyses 
be based on a compliant intention-to-treat group 
because of concerns that responses beyond 20 weeks 
would not be representative of the time impacted by 
the 16 week course of treatment. This amendment 
to the published trial protocol was approved within 
the statistical analysis plan. The primary intention-
to-treat analysis was therefore performed on a 
compliant group of patients (those who completed 
the 16 week primary outcome within a 14-20 week 
window), retaining patients in their randomised 
group. Secondary intention-to-treat analyses were 
performed on the pragmatic group—that is, all 
participants who completed the primary outcome, to 
include those additional patients seen after 20 weeks 
for their primary outcome assessment. Secondary 
analyses of the primary outcome also included 
adjustment for reflux finding score as a continuous 
measure (investigating non-linear relations using 
first order fractional polynomial transformation) and 
for other important clinical and personal baseline 
factors.
Analyses of secondary outcomes followed a similar 
strategy for questionnaire scores. We did not compare 
safety data statistically. Other data were analysed using 
statistical software package (STATA14). A statistical 
analysis plan following published guidance22 was in 
place before comparative analyses. No formal interim 
analyses were planned.
We aimed to recruit 332 patients. A mean difference 
of 3 points in RSI score at 16 weeks was deemed to 
be clinically important. With an assumed standard 
deviation of 7.723 a mean difference of 3.1 points 
equates to a standardised mean effect size of 0.4. 
A total of 266 participants (133 in each arm) were 
required to complete the trial intervention to be able 
to detect this standardised effect size with 90% power 
and 5% significance, inflated to 332 participants (166 
in each arm) to allow for 20% drop-out.
Patient and public involvement
Patients were involved in the design of the trial at 
the grant application stage and attended meetings of 
the trial steering committee. They helped define the 
need to explore the clinical management of throat 
and voice symptoms and aided the research team 
with the methodology, in particular confirming the 
appropriateness of the selected patient reported 
outcome measures. They will not be informed 
individually of the trial results, but the findings will be 
openly available on the trial’s website (www.toppits.
co.uk) after publication.
Results
Of 1427 patients initially screened for eligibility, 
346 were recruited through eight UK centres and 
randomised between April 2014 and February 2017: 
172 allocated to lansoprazole and 174 to placebo (fig 
1). Seventy (27%) of the recruited participants had 
received PPIs in the previous 12 months, and this 
was balanced across treatment groups. The drop-out 
rate was as anticipated in the design and was not 
different across treatment groups. Overall, 267 (77%) 
participants completed the 16 week primary outcome 
measure (the pragmatic intention-to-treat group), 
220 of whom completed it within the specified 14-20 
week window (the compliant intention-to-treat group). 
RSI questionnaires returned at 16 weeks were fully 
completed.
The compliant intention-to-treat group was 
representative of the trial population for personal 
characteristics (table 1): 126 (57%) were women, 
mean age was 54.5 (SD 13.1) years, and 107 (49%) 
had severe RSI-HB and overall mean RSI-HB scores of 
20.0 (SD 7.0) points, balanced across treatment arms 
(see supplementary table 2 for details of personal 
characteristics).
Treatment
In total, 265 of 346 (77%) participants had information 
on returned trial drug, of whom 262 (99%) were 
reported to have started treatment, taking at least one 
capsule. Of these 262 participants, 184 (70%) reported 
taking at least 90% of the full dose, balanced across 
treatment groups.
In total, 112 adverse events were reported in 74 
patients, 80 (71%) of which occurred during treatment: 
42 (70%) in the lansoprazole group and 38 (73%) in 
the placebo group. One severe adverse event, a rash 
that appeared after taking the allocated treatment, was 
categorised as probably related to treatment.
When participants were asked post-treatment 
to predict their allocated intervention, 42% of the 
lansoprazole group and 56% of the placebo group 
correctly identified their treatment at the end of the trial 
period. At 12 months, of the 213 responders, 54% were 
very satisfied and 28% were satisfied with the trial.
Primary outcome measure
An improvement in RSI (reduction in score) was observed 
overall in the compliant intention-to-treat group at 16 
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weeks, with a reduction in mean score from 21.9 (SD 
7.5) at baseline to 16.4 (SD 9.9). This improvement was 
observed in both treatment groups (table 2). Multilevel 
mixed effect linear regression of the RSI score at 16 weeks, 
adjusted for stratification factors at randomisation (site 
and RSI-HB severity category) showed baseline RSI-HB to 
be statistically significantly related to the RSI score at 16 
weeks (table 3). The RSI score at 16 weeks was estimated 
to be 8 points higher (worse) in participants in the severe 
severity stratum at baseline than those in the mild 
symptom severity stratum. No statistically significant 
difference was found in RSI scores at 16 weeks between 
treatment groups: after adjustment for stratification 
factors, the lansoprazole group scored 1.9 points higher 
(worse) than the placebo group (95% confidence interval 
−0.3 to 4.2, P=0.096). Supplementary table 3 displays 
the individual RSI items scores at baseline and 16 weeks.
After adjustment for other important clinical and 
personal baseline factors, and when analysing reflux 
finding score as a continuous measure, secondary 
analyses of the primary outcome in the wider pragmatic 
intention-to-treat group (table 3) gave similar results. 
No statistically significant difference was found in the 
RSI score at 16 weeks between the treatment groups 
in any of these planned analyses. At 12 months, RSI 
scores in participants in the lansoprazole group were 
2.5 points higher (worse) than those in participants 
in the placebo group (95% confidence interval −0.1 to 
5.0, P=0.06) (see supplementary table 5).
Secondary outcome measures
Analysis of the RSI-HB showed that the mean RSI score 
at 16 weeks in the lansoprazole group was 2.4 points 
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Fig 1 | Flow of participants through study
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confidence interval 14.5 to 18.1) v 13.9 (12.2 to 15.5) 
(table 2).
The CReSS scores improved (reduced) from baseline 
to 16 weeks in both treatment groups (table 2 and 
supplementary table 6).
The mean laryngopharyngeal health related quality 
of life scores showed similar noticeable improvement 
at 16 weeks in both treatment groups (table 2 and 
supplementary figure 1). In multilevel modelling the 
estimated overall laryngopharyngeal health related 
quality of life outcome score in the lansoprazole group 
was on average 2.9 higher (worse) than that in the placebo 
group (95% confidence interval −4.3 to 10.1; P=0.43).
Reflux finding scores at baseline were available 
for 256 participants (80% in the lansoprazole arm 
and 72% in the placebo arm). Mean baseline reflux 
finding scores were 9.7 (SD 4.1) in the lansoprazole 
group and 9.2 (3.8) in the placebo group. The baseline 
scores were not significantly related to the RSI score 
at 16 weeks using first order fractional polynomial 
transformations.
Discussion
This study found that lansoprazole offers no benefit 
over placebo for patients with persistent throat 
symptoms. No trends were in favour of lansoprazole. 
Patients who received lansoprazole on average 
reported worse improvement in symptoms than those 
receiving placebo. Treating patients for reported 
persistent throat symptoms “empirically” with PPIs, 
in the absence of specialist investigations, is common 
practice by healthcare practitioners worldwide. This 
should now be discouraged through evidence based 
treatment guidelines. Recent guidelines on chronic 
cough, which previously advocated trials of PPIs for 
presumed reflux related symptoms, have incorporated 
high level evidence and placebo controlled trials of 
PPIs and now state that acid reduction treatments 
should not be routinely prescribed for this condition.24
The practice of prescribing PPIs for these patients is 
based on several observational cases series showing 
improvement in symptoms over time with treatment. 
The inability of placebo controlled trials to replicate 
the benefits of PPIs in uncontrolled observational 
studies, however, suggests a misattribution of placebo 
enhanced spontaneous resolution in such single 
cohort reports.15 18 A systematic review of studies that 
used PPIs as empirical treatment for suspected reflux 
related throat symptoms identified 14 uncontrolled 
studies, one non-blind, non-randomised study with 
a control group of healthy volunteers, and six double 
blind, placebo controlled randomised trials from 
1994 to 2004.7 A lack of common outcome measures, 
potential selection bias, or inadequate blinding of the 
results were among typical limitations. An updated 
meta-analysis to 2005 of eight randomised controlled 
trials concluded that PPI treatment “may offer a modest 
but non-significant clinical benefit” over placebo.25 
A previous trial randomised 145 patients in a 2:1 
ratio to esomeprazole twice daily or matched placebo 
twice daily.8 The participants completed a Likert scale 
assessment of five symptoms: throat clearing, cough, 
globus, sore throat, and hoarseness. The participants 
identified their single most bothersome symptom 
at baseline. The primary outcome measure was the 
percentage of participants who had resolution of 
their most troublesome symptom. No difference was 
found between the treatment groups for the primary 
outcome measure, nor in secondary outcomes of 
laryngeal appearances, pH monitoring, or disease 
specific quality of life (laryngopharyngeal health 
related quality of life). Although discussions about 
methodology could be raised, it is difficult to conclude 
why this study did not diminish the enthusiasm for 
PPI use in this patient population. In our multicentre 
trial, we used a validated symptom reporting outcome. 
Table 1 | Baseline characteristics of participants
Variables













No (%) men 71 (41) 79 (45) 150 (43) 38 (37) 56 (47) 94 (43)
No (%) 
women
101 (59) 95 (55) 196 (57) 64 (63) 62 (53) 126 (57)
Age (years):
 Mean (SD) 53.5 (13.3) 50.8 (13.9) 52.2 (13.7) 55.3 (12.8) 53.8 (13.4) 54.5 (13.1)
 Range 21-84 20-80 20-84 23-84 21-80 21-84
Body mass index:
 Mean (SD) 28.2 (5.9) 28.1 (5.3) 28.1 (5.6) 28.5 (6.7) 28.4 (5.4) 28.5 (6.1)
 Range 11.3-56.9 18.3-49.1 11.3-56.9 11.3-56.9 18.3-49.1 11.3-56.9
Baseline RSI score:
 Mean (SD) 21.7 (7.4) 22.1 (7.0) 21.9 (7.2) 22.0 (8.0) 21.7 (7.1) 21.9 (7.5)
 Range 10-41 10-43 10-43 10-41 10-43 10-43
Baseline severity RSI-HB:
 Mean (SD) 20.0 (6.8) 20.1 (6.5) 20.1 (6.6) 20.3 (7.4) 19.8 (6.6) 20.0 (7.0)
 Range 10-38 10-38 10-38 10-38 10-38 10-38
Severity category†:
 Mild 91 (53) 93 (53) 184 (53) 53 (52) 60 (51) 113 (51)
 Severe 81 (47) 81 (47) 162 (47) 49 (48) 58 (49) 107 (49)
ITT=intention to treat; RSI=reflux symptom index; RSI-HB=laryngopharyngeal RSI items without the heartburn 
score.
*Only includes patients who completed the 16 week primary outcome measure within the 14 to 20 week 
window.
†Stratification factor at randomisation: mild (10 ≤RSI-HB ≤20), severe (RSI-HB >20).





Mean score at follow-up (95% CI)
Baseline 16 weeks* 12 months
RSI*:
 Lansoprazole 102 22.0 (20.4 to 23.6) 17.4 (15.5 to 19.4) 16.0 (13.6 to 18.4)
 Placebo 118 21.7 (20.5 to 23.0) 15.6 (13.8 to 17.3) 13.6 (11.7 to 15.5)
 Difference† 0.3 (−1.7 to 2.3) 1.8 (−0.8 to 4.4) 2.4 (−0.6 to 5.4)
RSI-HB:
 Lansoprazole 102 20.3 (18.8 to 21.7) 16.3 (14.5 to 18.1) 14.7 (12.4 to 16.9)
 Placebo 118 19.8 (18.6 to 21.0) 13.9 (12.2 to 15.5) 11.9 (10.1 to 13.7)
 Difference† 0.5 (−1.4 to 2.4) 2.4 (−0.0 to 4.8) 2.8 (0.5 to 5.1)
CReSS:
 Lansoprazole 102 50.3 (44.9 to 55.7) 38.9 (33.4 to 44.3) 36.6 (29.8 to 43.5)
 Placebo 118 51.1 (46.4 to 55.8) 34.7 (29.6 to 39.9) 31.8 (26.6 to 36.9)
 Difference† −0.8 (−7.9 to 6.3) 4.2 (−3.2 to 11.6) 4.8 (−3.5 to 13.1)
LPR-HRQL:
 Lansoprazole 102 28.9 (24.5 to 33.3) 20.5 (16.1 to 25.0) 18.8 (13.7 to 23.8
 Placebo 118 26.5 (22.5 to 30.5) 17.1 (13.3 to 21.0) 13.9 (10.0 to 17.8)
 Difference† 2.4 (−3.5 to 8.3) 3.4 (−2.4 to 9.2) 4.9 (−1.3 to 11.1)
RSI=reflux symptom index; RSI-HB=laryngopharyngeal RSI items without the heartburn score; 
CReSS=comprehensive reflux symptom score; LPR-HRQL=laryngopharyngeal health related quality of life.
*Primary outcome measure.
†Lansoprazole minus placebo is the difference in means (95% confidence intervals).








J: first published as 10.1136/bm
j.m





6 doi: 10.1136/bmj.m4903 | BMJ 2021;372:m4903 | the bmj
It is imperative that high quality clinical trials with 
negative outcomes, such as our trial, are incorporated 
into evidence based guidelines to bring about practice 
change. Our trial provides evidence for the medical 
profession to question indiscriminate use of PPIs and 
change empirical practices.
Strengths and limitations of this study
The strengths of our trial are that it was performed 
in several centres, reflecting national practices; 
comprised a representative patient population; was 
fully powered; and minimised bias through blinding.
Drop-out rate and compliance are problems in 
pragmatic clinical trials with patient reported outcome 
measures. Our trial was designed to recruit 266 patients 
with complete primary patient reported outcome data 
to detect a clinically important difference with 90% 
power. We recruited 346 patients, assuming a 20% 
drop-out rate, and a total of 267 patients completed the 
primary outcome measure (pragmatic set): 220 within 
the protocol timescale (compliant set). Drop-out was 
observed as anticipated, and the RSI questionnaires 
returned at 16 weeks were fully completed.
We recruited a realistic patient population providing 
generalisable results across NHS clinics. Our trial 
specifically assessed the effectiveness of lansoprazole 
for patients managed within a secondary care setting. 
However, the results seem essentially applicable to any 
proton pump inhibitor when used for the treatment of 
patients with persistent throat symptoms in primary 
and secondary care. No evidence was found to show 
superiority of one PPI over another for GORD, for 
which PPIs are well established as effective treatment. 
No such evidence exists for persistent throat symptoms 
either. The range of symptom severity in our trial 
included a few values that overlapped with the general 
population, based on the total RSI score. The range 
of symptom severity in participants in our trial thus 
reflects the spectrum of symptom severity encountered 
in primary care. It would be reasonable to assume 
that if lansoprazole, and by inference any PPI, is not 
effective for the population of patients recruited into 
our trial, then the drug would also be no more effective 
than placebo for patients with less severe symptoms.
One quarter of participants recruited to our trial had 
been prescribed a PPI in the preceding 12 months. The 
inclusion of these participants, after the appropriate 
wash-out period, was justified as it reflects a commonly 
encountered patient pathway within our pragmatic 
clinical trial design, and most receive a short course of 
a once daily regimen of PPI within primary care. This 
is a reasonable treatment trial for suspected heartburn 
or GORD, but our results show that patients whose 
throat symptoms respond to PPI are equally likely 
to respond to a placebo. Moreover, the PPI regimen 
for laryngopharyngeal symptoms in secondary care 
typically is twice daily for two to six months.10 Few 
if any of our participants who had previously tried 
PPIs had received this intensity of treatment, not least 
because doctors typically refer early to exclude occult 
disease.
Our trial could be criticised for lacking any 
objective measure of GORD within the methodology 
or for employing any such test as an inclusion criteria. 
However, we did address the use of PPIs in an empirical 
setting, which was a near universal practice at the time 
of our study. The use of techniques such as pH testing 
with impedance manometry is not common within 
otolaryngology practices in the UK. The inclusion of this 
technique, or of others, would have led to far greater 
expense to the trial funder, reduced the recruitment 
rate, and narrowed the trial’s applicability to specialist 
practice only. We recognise that many patients 
presenting with persistent throat symptoms have 
coexisting symptoms of GORD, as GORD symptoms are 
present in up to 20% of the population, and that these 
traditional symptoms of heartburn are commonly 
treated with PPIs. When the RSI was assessed through 
a postal survey in 378 respondents, about 50% of 
patients who met the criteria suggesting that persistent 
throat symptoms were due to reflux did so on the basis 
of their high traditional GORD symptom scores.16 We 
assessed the effectiveness of PPIs on persistent throat 
symptoms alone and not on coexisting symptoms 
of classic GORD. In adopting the inclusion criterion 
and a baseline severity stratification that removed 
the polysymptomatic GORD item from the RSI, we 
ensured that the outcomes pertained to persistent 
throat symptoms alone. The question remains as to 
how coexisting throat and GORD symptoms should 
be managed, and it is for this group of patients that 
research into specialist oesophageal investigations 
could be focused. When assessing the individual 
items of the RSI (see supplementary file), item 9, 
covering traditional GORD symptoms, generally had 
low reported scores and did not over 16 weeks change 
appreciably more in one group than the other. This 
observation suggests that it would be inappropriate 
to perform subgroup analysis of patients with higher 
GORD symptoms at baseline.
Unanswered questions and future research
Exploring alternative strategies to manage persistent 
throat symptoms requires well designed clinical trials, 
but these will only be possible when the practice of 
prescribing PPIs for these symptoms is discouraged. 
In our trial we found symptoms improved equally over 
Table 3 | Multilevel mixed effect linear regression models for primary outcome of reflux 
symptom index score at 16 weeks
β* (95% CI) SE (β)
Test 
statistic P value
Compliant ITT group (n=220)†:
 Lansoprazole (ref placebo) 1.93 (−0.35 to 4.20) 1.16 1.66 0.096
 RSI-HB baseline severity severe (ref mild) 8.17 (5.86 to 10.49) 1.18 6.92 <0.001
 Constant 14.35 (8.38 to 20.32) 3.04 4.71 <0.001
Pragmatic ITT group (n=267)†:
 Lansoprazole (ref placebo) 1.47 (−0.60 to 3.53) 1.06 1.39 0.17
 RSI-HB baseline severity severe (ref mild) 7.44 (5.35 to 9.54) 1.07 6.95 <0.001
 Constant 15.17 (9.27 to21.08) 3.01 5.03 <0.001
ITT=intention to treat; RSI-HB=laryngopharyngeal RSI items without the heartburn score.
*Adjusted by site (random effect).
†Estimate of treatment effect defined as estimated difference in 16 week score between randomised arms after 
adjustment for site and baseline severity.
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time between PPIs and placebo, but patients’ symptoms 
did not reduce to those of the general population. 
Hence a clear need exists to investigate more effective 
treatment strategies. Our results might support the 
renewed focus of research into the well established 
psychological concomitant throat symptoms in some 
patients—namely, anxiety, distress, depression, and 
coexisting persistent physical symptoms.26-28 Strategies 
that employ the techniques of reattribution (offering 
alternative explanations for causes of the symptoms), 
adjustments to lifestyle, and behaviour modification 
of speech or cognitive behavioural therapy28-32 seem to 
be relevant and a reasonable focus of further research. 
For such a common condition as persistent throat 
symptoms, it would seem appropriate to investigate 
whether elements of specialist proven treatments 
such as cough suppression techniques, voice therapy, 
management of globus, and cognitive behavioural 
therapy could be adapted into a clinically and cost 
effective self-directed care package for patients.
Great clinical interest has been shown in attributing 
throat and upper airway symptoms to manifestations 
of GORD. Interest is growing in weakly acidic, or non-
acidic, reflux, which would intuitively seem less likely 
to respond to PPIs yet contains the other important 
elements of gastric contents. Little evidence exists for 
the role of other factors that might reduce reflux related 
persistent throat symptoms, such as diet,33 lifestyle,34 
and alginates.23 Our trial does not refute reflux as 
a cause or contributing factor for some patients’ 
symptoms, and although reflux of gastric contents 
containing pepsin might be implicated in some 
patients, defining such individuals and appropriate 
management needs further research. This requires 
clarification on the use and interpretation of specialist 
investigations to identify reflux episodes and response 
to treatments.
Policy implications
No evidence supports the empirical use of PPIs to 
treat persistent throat and voice symptoms. The lack 
of any trend towards benefit with lansoprazole in our 
trial should discourage subgroup analysis hypotheses. 
The trial’s conclusions are particularly apt for the non-
specialist to whom the message has filtered through 
from otolaryngology case series evidence that PPIs are 
appropriate for this patient population. Our results 
also might be explained by an underestimation of the 
placebo effect in this group of patients and the failure 
of PPIs to affect non-acidic, or weakly acidic, reflux 
episodes.
Conclusions
A regimen of lansoprazole twice daily offered no 
symptomatic benefit over matched placebo for patients 
with persistent throat symptoms. Evidence supporting 
the empirical use of PPIs to treat persistent throat 
symptoms is lacking.
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